Company-reported prevalence
Hovilpri
Overview
| Field | Value |
|---|---|
| Drug | Hovilpri (pritelivir) |
| Indication | Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults |
| Disease | Herpes simplex virus (HSV) infection refractory or resistant to acyclovir in immunocompromised people; HSV-1 and HSV-2 infection in the general population |
| Company | Asahi Kasei Therapeutics (Asahi Kasei Corporation), worldwide rights since its acquisition of AiCuris Anti-infective Cures AG through Veloxis Pharmaceuticals in April 2026; AiCuris Anti-infective Cures AG, developer of pritelivir |
| Documents searched | AiCuris website, home, pipeline and products, products, about, early access, and events and presentations pages (accessed October 2026); AiCuris press releases, 2023 to April 2026; AiCuris corporate presentations (January 2024 and July 2025); Asahi Kasei acquisition briefing material and question-and-answer summary (February 2026); Asahi Kasei press release (April 2026); Asahi Kasei Therapeutics press releases (September and October 2026); Hovilpri healthcare professional website (accessed October 2026) |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
Eligible population: Asahi Kasei press release, April 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Eligible population (first-line and second-line treatment): Asahi Kasei acquisition briefing material, February 2026
“Estimated number of patients in the U.S.” (opens the source at this quote in a new tab)
“≈180,000” (opens the source at this quote in a new tab)
“5-20%” (opens the source at this quote in a new tab)
“(Depending on the underlying disease)” (opens the source at this quote in a new tab)
Cited source: 2.5 Asahi Kasei, undated
(opens the full-size image in a new tab)Number affected (severely immunocompromised people with HSV infection and acyclovir resistance): AiCuris corporate presentation, January 2024
“USA” (opens the source at this quote in a new tab)
“492,000 with HSV infections” (opens the source at this quote in a new tab)
“27,200 patients with ACV resistance” (opens the source at this quote in a new tab)
“128K ACV-R moderately immunocompromised patients” (opens the source at this quote in a new tab)
“Initial launch focused on primary market” (opens the source at this quote in a new tab)
Cited source: 2.4 Trinity, undated
(opens the full-size image in a new tab)Number affected (acyclovir-resistant patients by immunocompromising condition): AiCuris corporate presentation, July 2025
“EPIDEMIOLOGY US” (opens the source at this quote in a new tab)
“HSCT SOT Blood Cancer HIV Other” (opens the source at this quote in a new tab)
“N=23K N=43K N=186K N=516K N=950K” (opens the source at this quote in a new tab)
Cited source: None stated in the document.
(opens the full-size image in a new tab)Europe
Number affected (severely immunocompromised people with HSV infection and acyclovir resistance in the European Economic Area): AiCuris corporate presentation, January 2024
“EEA” (opens the source at this quote in a new tab)
“476,900 with HSV infections” (opens the source at this quote in a new tab)
“24,800 patients with ACV resistance” (opens the source at this quote in a new tab)
“136K ACV-R moderately immunocompromised patients” (opens the source at this quote in a new tab)
Cited source: 2.4 Trinity, undated
(opens the full-size image in a new tab)Global
Number affected (HSV-1 and HSV-2 infection): Asahi Kasei Therapeutics press release, October 2026
Cited source: 2.1 Harfouche 2025
(opens the full-size image in a new tab)Number affected (HSV-1 and HSV-2 infection): AiCuris press release, April 2026
Number affected (HSV-1 and HSV-2 infection): AiCuris corporate presentation, January 2024
Cited source: 2.2 World Health Organization 2025
(opens the full-size image in a new tab)Other countries and regions
No evidence found.
Geography not stated
Prevalence (share of immunocompromised patients developing drug resistance): AiCuris corporate presentation, January 2024
Cited source: 2.3 Morfin 2004
(opens the full-size image in a new tab)Sources the company cites
Harfouche 2025
Passage carrying the figure
World health organization 2025
Reference as the company lists it, corporate presentation, January 2024
Reference as the company lists it, press release, FDA priority review and ESCMID 2026 data
Passage carrying the figure
Morfin 2004
Reference as the company lists it
Passage carrying the figure
Not quoted: The reference gives no title, volume, or pages, and no 2004 document by Morfin in a publication named Clinical Virology could be identified.
Trinity, undated
Reference as the company lists it
Passage carrying the figure
Not quoted: Commissioned market research held on file by the company and not published.
Asahi kasei, undated
Reference as the company lists it
Passage carrying the figure
Not quoted: An internal company analysis that has not been published.
References
- AiCuris (2024) corporate presentation, January 2024 (opens in a new tab)
- AiCuris (2025) corporate presentation, July 2025 (opens in a new tab)
- AiCuris (2026) press release, FDA priority review and ESCMID 2026 data (opens in a new tab)
- Asahi Kasei (2026) acquisition briefing material, February 2026 (opens in a new tab)
- Asahi Kasei (2026) press release, completion of the AiCuris acquisition (opens in a new tab)
- Asahi Kasei Therapeutics (2026) press release, Hovilpri FDA approval (opens in a new tab)
- Harfouche 2025 (opens in a new tab)
- World Health Organization (2025) herpes simplex virus fact sheet (opens in a new tab)